Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
NCT ID: NCT00874549
Last Updated: 2013-09-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
216 participants
INTERVENTIONAL
2007-10-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To describe the rates of immediate reactions, solicited injection-site and systemic reactions, all unsolicited adverse events, and serious adverse events following vaccination with either Menactra® vaccine or Menomune® vaccine.
Immunogenicity:
To evaluate the immune response to serogroups A, C, Y, and W-135 in each of the four study groups.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: Menomune Day 0
Participants received a single dose of Menomune® vaccine on Day 0.
Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide
0.5 mL, Subcutaneous
Group 2: Menactra® Day 0 x 2
Participants received two single-dose injections of Menactra® vaccine on Day 0
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL, Intramuscular
Group 3: Menactra® Day 0 and 14
Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL. Intramuscular
Group 4: Menactra® Day 0 and 28
Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL, Intramuscular
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide
0.5 mL, Subcutaneous
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL, Intramuscular
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL. Intramuscular
Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
0.5 mL, Intramuscular
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 56 years of age or older at the time of vaccination.
* Signed Institutional Review Board (IRB)-approved informed consent form.
* Able to attend all scheduled visits and to comply with all trial procedures.
* For a woman, inability to become pregnant or a negative urine pregnancy test at the time of enrollment.
Exclusion Criteria
* Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc) that is unstable or that might 1) interfere with the ability to participate fully in the study or 2) interfere with evaluation of the vaccines.
* Known or suspected impairment of immunologic function.
* Febrile illness within the last 72 hours or an oral temperature ≥ 100.4ºF at the time of inclusion.
* History of documented invasive meningococcal disease or previous meningococcal vaccination.
* Known or suspected receipt of a diphtheria-containing vaccine within the preceding 2 years.
* Administration of immune globulin or other blood products within the last three months, or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting \< 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
* Systemic antibiotic therapy within the 72 hours prior to collection of any blood samples.
* Received any vaccine in the 28-day period prior to enrollment or scheduled to receive any vaccination through Visit 2 for Groups 1 and 2 and through Visit 3 for Groups 3 and 4. Influenza vaccines may be received 2 weeks before or after a study vaccination.
* Suspected or known hypersensitivity to latex or to any of the components of either Menactra® vaccine or Menomune® vaccine.
* Previous personal history of Guillain-Barré syndrome.
* Not available for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.
* In females of childbearing potential, a positive or equivocal urine pregnancy test at enrollment.
* A nursing mother.
* Participation in another interventional clinical trial in the 4 weeks preceding enrollment or planning to participate in another interventional clinical trial during the planned period of this study.
* Current use of alcohol or recreational drugs that may interfere with the subject's ability to comply with trial visits or procedures.
* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.
* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
56 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi Pasteur, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Sanofi Pasteur Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scottsdale, Arizona, United States
Bardstown, Kentucky, United States
Albuquerque, New Mexico, United States
West Jordon, Utah, United States
Seattle, Washington, United States
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MTA29
Identifier Type: -
Identifier Source: org_study_id